CORRECTION article

Front. Immunol.

Sec. Immunological Tolerance and Regulation

Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1632381

Correction: Investigation of potential protein biomarkers for the screening of placentalmediated fetal growth restriction disorders using targeted proteomics Olink technology

Provisionally accepted
Xinyao ZhouXinyao Zhou1Wuqian WangWuqian Wang2Luan ChenLuan Chen3Yingjun YangYingjun Yang4Xing WeiXing Wei1Jia ZhouJia Zhou1Kuan SunKuan Sun1Ping TangPing Tang5Xiaofang SunXiaofang Sun2Shengying QinShengying Qin3Luming SunLuming Sun4*
  • 1Shanghai First Maternity and Infant Hospital, Shanghai, Shanghai Municipality, China
  • 2Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong Province, China
  • 3Shanghai Jiao Tong University, Shanghai, Shanghai Municipality, China
  • 4Xinhua Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, Shanghai Municipality, China
  • 5Jiaxing Maternity and Child Health Care Hospital, Jiaxing, Zhejiang, China

This article is a correction to:

  1. Investigation of potential protein biomarkers for the screening of placental-mediated fetal growth restriction disorders using targeted proteomics Olink technology

    1. Read original article

The final, formatted version of the article will be published soon.

Select one of your emails

You have multiple emails registered with Frontiers:

Notify me on publication

Please enter your email address:

If you already have an account, please login

You don't have a Frontiers account ? You can register here

Corrigendum: Investigation of potential protein biomarkers for the screening of placentalmediated fetal growth restriction disorders using targeted proteomics Olink technology Correspondence: Luming Sun: luming_sun@163.com; Shengying Qin: chinsir@sjtu.edu.cnKeywords: same as original articleCorrigendum on: Zhou X, Wang W, Chen L, Yang Y, Wei X, Zhou J, Sun K, Tang P, Sun X, Qin S and Sun L(2025) Investigation of potential protein biomarkers for the screening of placentalmediated fetal growth restriction disorders using targeted proteomics Olink technology. Front. Immunol. 16:1542034. doi: 10.3389/fimmu.2025.1542034 Error in Figure/TableIn the published article, there was an error in [ Figure2B] as published. [We mistakenly showed incorrect numbers on the pie chart]. The corrected [Figure2] and its caption **[FIGURE 2Descriptive statistics of clinical information of FGR patients. (A) Gestational Week for Collection of Maternal Peripheral Blood for FGR patients and control samples; (B) Blood flow conditions for FGR patients; (C) Combined symptoms for FGR patients] appear below. The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Keywords: Fetal growth restriction (FGR), Olink proteomics platform, proximity extension assay (PEA), biomarkers, targeted proteomics analysis

Received: 21 May 2025; Accepted: 05 Jun 2025.

Copyright: © 2025 Zhou, Wang, Chen, Yang, Wei, Zhou, Sun, Tang, Sun, Qin and Sun. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Luming Sun, Xinhua Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200092, Shanghai Municipality, China

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Supplementary Material